451 related articles for article (PubMed ID: 16930924)
1. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci.
Scheetz MH; Qi C; Noskin GA; Warren JR; Postelnick MJ; Malczynski M; Huang J; Zembower TR
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):407-13. PubMed ID: 16930924
[TBL] [Abstract][Full Text] [Related]
2. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center.
Dobbs TE; Patel M; Waites KB; Moser SA; Stamm AM; Hoesley CJ
J Clin Microbiol; 2006 Sep; 44(9):3368-70. PubMed ID: 16954275
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
4. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.
Rahim S; Pillai SK; Gold HS; Venkataraman L; Inglima K; Press RA
Clin Infect Dis; 2003 Jun; 36(11):E146-8. PubMed ID: 12766857
[TBL] [Abstract][Full Text] [Related]
5. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid.
Wareham DW; Abbas H; Karcher AM; Das SS
J Infect; 2006 Apr; 52(4):300-4. PubMed ID: 16099052
[TBL] [Abstract][Full Text] [Related]
6. Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility.
Scheetz MH; Knechtel SA; Postelnick MJ; Malczynski M; Qi C
Pharmacotherapy; 2010 Dec; 30(12):1221-8. PubMed ID: 21114389
[TBL] [Abstract][Full Text] [Related]
7. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
Efe S; Sinirtaş M; Ozakin C
Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
Chou YY; Lin TY; Lin JC; Wang NC; Peng MY; Chang FY
J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
[TBL] [Abstract][Full Text] [Related]
9. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms.
Sandoe JA; Wysome J; West AP; Heritage J; Wilcox MH
J Antimicrob Chemother; 2006 Apr; 57(4):767-70. PubMed ID: 16464896
[TBL] [Abstract][Full Text] [Related]
10. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
Seedat J; Zick G; Klare I; Konstabel C; Weiler N; Sahly H
Antimicrob Agents Chemother; 2006 Dec; 50(12):4217-9. PubMed ID: 16982791
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
12. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.
Johnson AP; Tysall L; Stockdale MV; Woodford N; Kaufmann ME; Warner M; Livermore DM; Asboth F; Allerberger FJ
Eur J Clin Microbiol Infect Dis; 2002 Oct; 21(10):751-4. PubMed ID: 12415476
[TBL] [Abstract][Full Text] [Related]
13. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium.
Till M; Wixson RL; Pertel PE
Clin Infect Dis; 2002 May; 34(10):1412-4. PubMed ID: 11981739
[TBL] [Abstract][Full Text] [Related]
14. Optimizing therapy for vancomycin-resistant enterococci (VRE).
Linden PK
Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid.
Santayana EM; Grim SA; Janda WM; Layden JE; Lee TA; Clark NM
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):39-42. PubMed ID: 22749382
[TBL] [Abstract][Full Text] [Related]
16. Linezolid resistant enterococcus faecium.
McNicholas S; Hanahoe B; Higgins F; McAnena O; Corbett-Feeney G; Cormican M
Ir Med J; 2008; 101(7):225-6. PubMed ID: 18810787
[No Abstract] [Full Text] [Related]
17. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
Gonzales RD; Schreckenberger PC; Graham MB; Kelkar S; DenBesten K; Quinn JP
Lancet; 2001 Apr; 357(9263):1179. PubMed ID: 11323048
[TBL] [Abstract][Full Text] [Related]
18. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
20. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium.
Pai MP; Rodvold KA; Schreckenberger PC; Gonzales RD; Petrolatti JM; Quinn JP
Clin Infect Dis; 2002 Nov; 35(10):1269-72. PubMed ID: 12410489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
